What Happened When California Let Glaucoma Patients Try THC | Research

The takeaway

A California compassionate access program enrolled only 9 glaucoma patients despite strong physician interest, and all discontinued treatment within 9 months due to side effects and unsustained pressure reduction.

Read this if you have heard that cannabis treats glaucoma and want to know what actually happened when patients tried it.

All 9 patients discontinued THC treatment within 1-9 months

What the researchers found

Despite 20 approved ophthalmologist investigators and strong initial interest, only 9 patients enrolled in the Cannabis Therapeutic Research Program. All patients showed an initial decrease in intraocular pressure, and treatment goals were met in 4 of the 9 patients. However, the pressure reductions were not sustained over time, and every patient elected to discontinue treatment within 1 to 9 months.

Reasons for discontinuation were varied but related to the development of tolerance to the pressure-lowering effect and significant systemic side effects. The authors concluded that while cannabinoids can lower eye pressure, tolerance and toxicity appeared to limit their usefulness as a glaucoma treatment.

Why it matters

This real-world program provided a rare look at what happened when glaucoma patients actually tried cannabinoid treatment over months rather than in single-dose laboratory studies. The finding that all patients voluntarily stopped treatment due to tolerance and side effects was a powerful practical counterpoint to the common belief that cannabis is an effective glaucoma treatment.

The numbers in context

Twenty ophthalmologists were approved as investigators. Nine patients enrolled. Four of nine met the investigator's therapeutic goal initially. All nine discontinued treatment within 1 to 9 months.

How the study worked

This was an uncontrolled, unmasked, nonrandomized study conducted under the California Cannabis Therapeutic Research Program. Patients with end-stage glaucoma unresponsive to conventional treatments received either oral THC capsules or inhaled marijuana alongside their existing treatment regimen. The program was designed for compassionate access rather than rigorous clinical investigation.

What this study cannot tell us

The uncontrolled, unmasked design prevents definitive conclusions about efficacy. The very small sample (9 patients) limits generalizability. The program enrolled only end-stage, treatment-resistant patients who may not represent typical glaucoma cases. No standardized outcome measures or dosing protocols were described.

How to read the evidence

This was an uncontrolled compassionate access program with only 9 patients and no comparison group, providing preliminary-level evidence.

When this study was published

Published in 2002. Major ophthalmological organizations have since issued statements against cannabis as a glaucoma treatment.

The bigger picture

This study reinforced what other research was finding: while cannabinoids can acutely lower eye pressure, the effect does not last, tolerance develops, and side effects accumulate. Major ophthalmological organizations subsequently issued statements against recommending cannabis for glaucoma, citing these limitations.

Questions still open

Why was enrollment so low despite strong physician interest? Would different cannabinoid formulations or delivery methods have produced more sustained effects? Could cannabinoids play a complementary role at lower doses alongside conventional treatments?

Common questions

Why don't eye doctors recommend cannabis for glaucoma?

This study showed the practical problems: while cannabis initially lowers eye pressure, the effect fades as tolerance develops, side effects accumulate, and patients stop treatment. Glaucoma requires consistent 24-hour pressure control that cannabis cannot provide.

Why did so few patients enroll when many doctors were interested?

The paper noted the disconnect between physician interest and actual enrollment but did not fully explain it. Possible factors include patient reluctance, strict eligibility criteria (end-stage disease only), and the challenges of participating in a regulated cannabis program.

Read the original research

Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma.

Transactions of the American Ophthalmological Society, 100, 215-22; discussion 222-4

View on PubMed ↗

Citation

Flach, Allan J. (2002). Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma.. Transactions of the American Ophthalmological Society, 100, 215-22; discussion 222-4.